INTRODUCTION. British Journal of Obstetrics and Gynaecology March 2000, Vol107, pp
|
|
- Gary Carroll
- 5 years ago
- Views:
Transcription
1 British Journal of Obstetrics and Gynaecology March 2000, Vol107, pp The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women treated with hormone replacement therapy May Wahab Clinical Research Fellow/Specialist Registrar, John Thompson Senior Lecturer, Farook Al-Azzawi Senior LecturedConsultant (Gynaecology) Gynaecology Research Group, Department of Obstetrics and Gynaecology, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infinnary Objective To assess the value of identifying endometrial structural abnormalities at baseline hysteroscopy in predicting the pattern of bleeding in postmenopausal women treated with hormone replacement therapy. Design A randomised, double-blind, dose-ranging study. Setting A teaching hospital in the UK. Population One hundred and seventy-six healthy postmenopausal women. Methods Women were randomised to receive one of four doses of oral trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day), from day 15-28, and a daily dose of 2 mg oral micronised oestradiol for six treatment cycles. Women completed diaries in which the bleeding episodes were recorded. Hysteroscopy under local anaesthesia and endometrial biopsy were performed at baseline and on day 24 of the last treatment cycle. Results Women with submucous fibroids had more prolonged (P = 0-026) and heavier (P = 0.002) progestogen-associated bleeding (odds ratio 4.54). The incidence of intermenstrual bleeding, but not its duration or severity, was higher in women with submucous fibroids (P = 0.017). There was a clear dose-dependent effect of trimegestone, with a consistently later onset of progestogen-associated bleeding occurring with increasing doses of trimegestone (P < O.OOl), and such episodes became progressively lighter and of shorter duration over time (P < 0.001). Conclusion Hysteroscopic evaluation of the endometrial cavity in women treated with hormone replacement therapy, predicts the occurrence of heavy and unscheduled bleeding. INTRODUCTION The use of hormone replacement therapy (HRT) in postmenopausal women has been limited by medicationinduced adverse effects, and in particular, the induction of uterine bleeding'. In 50% of women uterine bleeding, particularly if unpredictable or heavy, is the most common cause of noncontinuation of HRT2. The long term use of HRT has far-reaching effects in improving the quality of life, preventing osteoporosis, cardiovascular disease and Alzheimer's disease3". Therefore, factors responsible for unscheduled bleeding, if identified and Correspondence: Dr F. Al-Azzawi, Department of Obstetrics and Gynaecology, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK. treated, may enhance the provision of a healthy existence in post-reproductive years. Hysteroscopically identified endometrial structural abnormalities in postmenopausal women are associated with unscheduled uterine bleeding while on HRT. Of all fibroids, the submucous type seems to be the most symptomatic6. In our previous report 47.6% of women with irregular or heavy bleeding on HRT had structural lesions on hysteroscopic assessment'. Similar results (46.7%) were reported by Nagele et alx. Akkad et al9 found that the presence of submucous fibroids was associated with a three-fold increase in the risk of abnormal uterine bleeding in premenopausal women and a two-fold increase in the risk of abnormal withdrawal bleeding in peri- and postmenopausal women using HRT. While endometrial polyps are invoked as a cause of abnormal bleeding 0 RCOG 2000 British Journal of Obstetrics and Gynaecology 329
2 330 M. WAHAB ET AL. patterns'', our previous reports failed to show such a ~orrelation'.~. Trimegestone is a novel norpregnane progestin with potent progesterone receptor and very low androgen receptor affinities, and no detectable affinity to oestrogen receptors]'. Such a profile makes this progestogen a suitable compound to investigate in combined HRT. We have demonstrated that the dose of trimegestone can dramatically influence the pattern of bleeding'*. Nevertheless, some of the women who received the higher doses of trimegestone experienced early onset, heavy and prolonged progestogen-associated bleeding, while others who received the lower doses had late onset and light menstrual discharge of short duration, and therefore, mechanisms other than the dose of trimegestone seem to be relevant in modulating endometrial shedding. The aim of this study was to assess the predictive value of hysteroscopically diagnosed endometrial structural abnormalities on the pattern of bleeding in postmenopausal women treated with trimegestone-based sequential HRT. METHODS Women recruited into this study were referred by their general practitioners to the Menopause Research Unit, Leicester University School of Medicine and Bioscience. The protocol was approved by the local ethics committee and all women signed their informed consent. This cohort of 176 women, was part of a multicentre double-blind dose-ranging study population of 256 women. Women included in this study were healthy, aged years, with an intact uterus, whose menopausal status required to fulfil one of the following criteria: 1. At least six months had elapsed since the last menstrual period, with follicle-stimulating hormone and oestradiol in the postmenopausal range. 2. Had used HRT continuously for more than two years. 3. Had been on HRT for at least one year with pre-treatment follicle-stimulating hormone and oestradiol levels in the postmenopausal range. None had received any form of sex steroid treatment for six weeks before the commencement of study medications. Those who had ever used oestradiol implants were excluded. Tests for liver and renal function were performed and those women with abnormalities were excluded. All women over the age of 50 had a normal mammogram within three years, and normal cervical smears within the previous six months. General, breast, and pelvic examinations were conducted to confirm normality. Pelvic sonography was performed to measure the size of the uterus, endometrial thickness and to assess the adnexa. All endometrial biopsies were evaluated by two independent pathologists, blinded to the dose of trimegestone. To evaluate the presence of endometrial structural abnormalities, all women underwent diagnostic hysteroscopy under local anaesthesia, as previously described'. Submucous fibroids and endometrial polyps were differentiated by their appearance and consistency. Submucous fibroids were graded according to the degree of protrusion into the endometrial cavity into 3 grades: I, II and III, depending on how much of an estimated sphere is protruding into the endometrial cavity: up to 1/3, up to 213 or > 2/3, respectively. The endometrium was sampled using the Vabra curette and women with evidence of hyperplasia or carcinoma were excluded. Additional sex steroid treatments were not allowed during the study and women who were using treatments known to interfere with steroid metabolism were excluded from the study. At the final visit, general, breast, and pelvic examination were repeated, pelvic sonography, hysteroscopy under local anaesthesia and endometrial biopsy were performed on day 24 of the last treatment cycle. In the dose-ranging, double-blind, parallel groups study, women were randomised to receive treatment medications for six cycles. The study treatment was randomly assigned to the randomisation numbers (using SAS statistical package, SAS institute Inc, Cary, North Carolina, USA). The four doses of trimegestone were randomised on a 1 : 1 : 1: 1 basis. Women were numbered consecutively in the order in which they entered the study. Each treatment cycle consisted of oral micronised oestradiol 2 mg/day (RU 3499) for 28 days and oral trimegestone (Hoechest Marion Roussel, Romianville, France) (0.05, 0.1, 0.25, or 0.5 mg) from days The first visit was a pre-study assessment for inclusion, 2-3 weeks prior to commencement of 168 days treatment. Women attended the unit at the end of the third cycle of treatment and on the 24th day of the sixth treatment cycle. If a woman could not attend on that day, a seventh treatment cycle was prescribed. Women completed menstrual diaries for each treatment cycle, in which the severity of the bleeding was subjectively scored as: 0 = no bleeding, 1 = spotting, 2 = slight bleeding, 3 = moderate bleeding, and 4 = heavy bleeding. The total bleeding score was taken as the sum of the daily scores for each cycle. The diaries were collected at each visit and were checked for accuracy and completeness. These diaries also served as an additional parameter to check compliance since a box had to be ticked when the tablets were taken. The medication packs were collected and any remaining tablets were counted. Where less than 80% of the medications were used, noncompliance was marked and the woman withdrawn from the study. All adverse events and concomitant medications were checked at each visit.
3 UTERINE BLEEDING IN WOMEN TREATED WITH HORMONE REPLACEMENT THERAPY 331 A bleeding episode was defined as an episode of uterine bleeding which lasts for one or more days with at least one clear day before and after. The progestogenassociated bleeding was defined as the longest bleeding episode which starts between day 22 of one cycle and day 7 of the next treatment cycle inclusive. All other bleeding episodes were called intermenstrual bleeding. Only completed diaries were analysed for the purpose of this study. The bleeding data in cycles in which the endometrial biopsy was taken were excluded. The day of commencement of the oestrogen phase of the cycle was deemed as a fixed point of reference (i.e. day 1). Statistics Data were collected on up to seven treatment cycles and were analysed using mixed effects regression models. For continuous data, such as day of onset of progestogen-associated bleeding, duration and severity of the bleeding, the residual maximum likelihood was usedi3 to fit the model. For binary data, such as the occurrence of intermenstrual bleeding, a generalised linear mixed model with binomial errors was used 4. Calculations were made using GENSTATI5. RESULTS Between November 1994 and December 1995, 176 women were randomised to one of the four dose groups of trimegestone, 169 were treated and 131 completed the study, while only 129 women were evaluated for endometrial analysis, as two women declined to have a biopsy at the end of the study. There were seven women who did not start treatment after randomisation and were withdrawn from the study as a result of being; lost to follow up (n = 3), protocol violation (n = 3) and adverse events (n = 1). Women randomised into the study had an overall mean (SD) age of 52.5 years (5.1), weight of 64.2 kg (103, height of cm (6.7) and body mass index of 24-8 kg/cm2 (3.4) (Table 1). There were no differences between the treatment groups in terms of age, race, height, weight, body mass index and smoking habits. The number of women who completed the study were: 33, 33, 37 and 28 in dose groups 0.05 mg, 0.1 mg, 0.25 mg, and 0.5 mg, respectively. Thirty-eight women did not complete the study due to: bleeding problems (n = 9), mastalgia (n = 6), gastrointestinal tract symptoms (n = l), headaches (n = 4), depression (n = 2), pruritus (n = 3), muscular cramps (n = l), weight gain (n = l), weight loss (n = l), gastrointestinal tract cancer (n = l), breast cancer (n = l), deep venous thrombosis (n = 2) women s request (n = 4) and lost to follow up (n = 2). There was no statistically significant difference between the number of women who withdrew from each trimegestone dose group. Six hundred and ten diaries were analysed. All women who completed the study experienced an episode of bleeding in each treatment cycle. The diaries were evaluated for the day of onset, duration and severity of the progestogen-associated bleeding and intermenstrual bleeding episodes. Submucous fibroids were identified at baseline hysteroscopy in 4, 7, 5 and 7 women in the 0.05 mg, 0.1 mg, 0.25 mg and 0.5 mg dose groups, respectively (Fig. 1). Endometrial polyps were identified in 3, 3, 5 and 2 women assigned to 0.05 mg, 0.1 mg, 0.25 mg and 0.5 mg dose groups, respectively. Age, duration of the menopause, previous use of HRT, Table 1. Demographic characteristics of the treated women, and the number of withdrawals in each dose group. Values are given as n or mean (SD). BMI = body mass index. Dose (mg) TOTAL No. of women treated Race White Black Asian Age (yea) 52.5 (5.1) 52-6 (5.1) 52.6 (5.3) 53.2 (4.3) 51.5 ( 56) Weight (kg) 64.2 (10.5) 64.3 (9.7) 64.1 (9.3) 65.3 (7.5) 62.8 (9.3) Height (cm) (6.7) (7.5) (6.9) (6.9) (5.3) BMI (kg/m2) 24.8 (3.4) 24.9 (3.6) 25 (3.4) 25 (3.3) 24.2 (2.8) Smoking Smoker Given up smoking Never a smoker Women withdrawn Women who completed the study
4 332 M. WAHAB ET AL. n=4 n=7 n=5 n=7 CYil: $ ) 0 L Dose groups of trimegestone (mg) Fig. 1. The incidence of hysteroscopically identified submucous fibroids, and their grades. It can be noted that a woman may have had more than one fibroid (n = number of women in a particular dose group). height, weight, or body mass index did not influence the bleeding pattern among the four trimegestone dose groups. Analysis of the bleeding diaries showed that the episodes of progestogen-associated bleeding lasted longer (P = 0.026) and were heavier (P = 0.002) in the presence of submucous fibroids (Table 2). This effect was apparent only in the higher three doses of trimegestone. The odds of having mean total bleeding score of over (the 3rd quartile) was more than four times higher in women with submucous fibroids than without (odds ratio 4-54,95% CI 1.45, 14-26). Intermenstrual bleeding occurred more frequently in the presence of submucous fibroids (P = 0.017) (Fig. 2). However, there was no statistically significant association between submucous fibroids and the duration (P = 0-83) or the severity (P = 0.27) of the intermenstrual bleeding (data not shown). There was no statistically significant effect of the endometrial polyps on any of the bleeding parameters studied. The progestogen-associated bleeding episodes occurred progressively later in the treatment cycle (P c 0.001) with the increase in the dose of trimegestone. The progestogen-associated bleeding episodes were consistently shorter (P < 0.001) and lighter (P c 0.001) in the higher doses (Table 1). The episodes of intermenstrual bleeding were lighter in higher doses (P = 0.035), but there was no demonstrable dose-response effect on the incidence or the duration of the intermenstrual bleeding. The histological assessment of the endometrium at the end of the study showed secretory changes (96%), proliferative changes (1-6%), inactive endometrium (0.8%), inadequate samples for histological assessment (0-8%), and one case of simple hyperplasia which was found in a woman receiving 0.5 mg of trimegestone. There was no statistically significant difference in the histological type of the endometrium between the four treatment groups. DISCUSSION The pathogenesis of abfiormal uterine bleeding in association with submucous fibroids is not fully understood and a number of explanations have been suggested. Sampson ( 1912)16 found that there were structural and branching abnormalities in the arterial blood supply to these fibroids, although an obstruction to the uterine venous plexus can lead to generalised or focal endometrial venous ectasia and consequently more prolonged and heavier blood loss. This however remains an unconfirmed possibility. This study demonstrates that hysteroscopically identified submucous fibroids are predictive of heavier and longer progestogen-associated bleeding, with a higher incidence of intermenstrual bleeding. The effect of submucous fibroids on the duration and seventy of the progestogen-associated bleeding episodes was not apparent Table 2. The day of onset, duration, and severity, of the progestogen-associated bleeding patterns in women with and without submucous fibroids specified for dose groups. Values are given as n or mean (SD), the SD are across the cycles and include variations within and between the women. TBS =total bleeding score. Dose groups (mg) No. of women Cycles Day of onset Duration TBS Women with submucous fibroids (3.5) 7.0 (2.6) 16.3 (7.0) (2.9) 7.9 (2.7) 19.5 (6.6) (2.3) 6.9 (2.4) 14.5 (6.1) (1.3) 5.8 (1.6) 13.5 (3.9) Women without submucous fibroids (3.03) 7.5 (2.7) 16.6 (6.4) (3.29) 6.7 (2.4) 14.6 (5.4) (3.19) 5.8 (2.6) 11.7 (5.8) (3.25) 4.5 (1.5) 10.7 (4.1)
5 UTERINE BLEEDING IN WOMEN TREATED WITH HORMONE REPLACEMENT THERAPY 333 C c Z Trimegestone (mg) Fig. 2 The incidence of intermenstrual bleeding (IMB) in women with and without submucous fibroids in the four doses of trimegestone. incidence of IMB; a women with no submucous fibroids: 0 women with submucous fibroids. in the lowest dose of trimegestone (0.05 mg), which may be due to fewer women with submucous fibroids in this group. Alternatively, there may be a dose threshold below which the dose-response relationship no longer exists. In the generalised linear mixed model, the occurrence of submucous fibroids in all women in this cohort was considered together, and therefore allowed for the identification of submucous fibroids as a significant predictor of the heavy, prolonged progestogen-associated bleeding and of intermenstrual bleeding. However, the number of women with submucous fibroids in each dose group was too small to allow a separate analysis of the effect of the number and grade on the pattern of bleeding. The lack of association of the unscheduled pattern of bleeding with endometrial polyps confirms our previous report^^,^. The dose of trimegestone did not affect the incidence of intermenstrual bleeding, while the presence of submucous fibroids predicted its occurrence. Therefore, we advocate hy steroscopic assessment rather than changing the dose of trimegestone in women with intermenstrual bleeding on hormone replacement therapy. While it may be difficult to argue the necessity of performing hysteroscopy for all women contemplating HRT, it is necessary to evaluate the endometrial cavity hysteroscopically to exclude the presence of submucous fibroids in those who experience heavy or unscheduled bleeding while receiving HRT. Removal of submucous fibroids by local excision such as laser ablation or electro-resection may rectify the abnormal bleeding pattern in these women18. In our previous report of the whole study population of 256 women12, randomised to the four trimegestone groups, a dose-dependent modulation of uterine bleeding was evident. Higher trimegestone doses induced later day of onset, progressively lighter and shorter episodes of progestogen-associated bleeding. The analysis of the bleeding diaries in this study of 176 women treated in our centre, confirmed the dominant effect of the dose of trimegestone on the day of onset, severity and duration of the progestogen-associated bleeding. The incidence of simple cystic hyperplasia in women on hormone replacement therapy is 7%19, and there was one case of simple hyperplasia in the 0.5 mg dose, which could have risen by chance. In this study, it was not possible to evaluate a potential interaction between the dose of the trimegestone and the presence of submucous fibroids in view of the small number of women with submucous fibroids in each dose groups. In conclusion, we recommend hysteroscopic assessment of women with abnormal bleeding patterns on HRT regimen, to exclude the presence of submucous fibroids. Acknowledgements This study was supported by Hoechest Marion Roussel Romainville, France and Wyeth-Ayerst, USA, in a joint development programme. References 1 Al-Azzawi F, Habiba M. Regular bleeding on hormone replacement therapy: a myth? Br J Obstet Gynaecol 1994; 101: Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obster Gynecol 1990; 75 (SUPPI): Daly E, Vessey MP, Barlow D, Gray A, McPherson K, Roche M. Hormone replacement therapy in a risk-benefit perspective. Maruritas 1996; 23: Akkad A, Hartshorne T, Bell PRF, Al-Azzawi F. Carotid plaque regression on oestrogen replacement: a pilot study. Euro J Vas Endo Surgery. 1996; 11: Paganini HA, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996; 156: Itzkowic D. Submucous myoma: Clinical profile and hysteroscopic management. Aust NZ J Obsret Gynecoll993; 33: Downes E, Al-Azzawi F. The predictive value of outpatient hysteroscopy in a menopause clinic. Br J Obsret Gynaecol 1993; 100: Nagele F, O Connor H, Baskett TF, Davies A, Mohammed H, Magos AL. Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding. Fertil Sreril 1996; 65: Akkad AA, Habiba MA, Ismail N, Abrams K, Al-Azzawi F. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1995; 86: MacKenzie JZ, Bibby JG. Critical assessment of dilatation and curettage in 1029 women. Lancer 1978; ii: Philibert D, Bouchoux F, Degryse M et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol1999; 13: Al-Azzawi F, Wahab M, Thompson J, Whitehead M, Thompson W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod 1999; 14: Patterson HD, Thompson R. Recovery of inter-block information when block sizes are unequal. Biometrika 1971; 58:
6 334 M. WAHAB ET AL. 14 Brestlow NE, Clayton DG. Approximate inference in generalised linear mixed models. JAm Stat Ass 1993; GENSTAT 5 Committee. GENSTAT 5 Release 3 Reference Manual. Oxford Clarendon Press, Sampson JA. The blood supply of uterine myomata. Surg Gynaecol Obstet 1912; 14: Farrer-Brown G, Beilby JOW, Tarbit MH. Venous changes in the endometrium of myomatous uteri. Obstet Gynecoll971; 38: Hallez JP. Myomectomies by endo-uterine resection. Curr Opin Obstet Gynecol1996; 8: Sturdee DW, Wade-Evans T, Paterson MEL, Studd J W. Relations between bleeding pattern, endomehial histology, and oestrogen treatment in menopausal women. BMJ 1978; 1: Accepted 4 October 1999
Menstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationHeavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist
Heavy Menstrual Bleeding Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist Why is HMB so important? 1:20 women aged 30-49 consult their GP with HMB Once referred to gynaecologist, surgical
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More informationOut Patient Hysteroscopy Unit GUIDELINES
Out Patient Hysteroscopy Unit GUIDELINES 1 AIMS The aim of the menstrual assessment clinic [MAC] (incorporating outpatient hysteroscopy) at Queen Charlotte s and Chelsea Hospital will be to provide a one-stop
More informationInvestigation of abnormal uterine bleeding in perimenopausal women by hysteroscopy and endometrial biopsy
Gynecol Surg (2005) 2: 51 55 DOI 10.1007/s10397-004-0076-2 CURRENT REFERENCES I. Stamatellos Æ P. Stamatopoulos Æ D. Rousso E. Asimakopoulos Æ C. Stamatopoulos Æ I. Bontis Investigation of abnormal uterine
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More information5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist
Abnormal Uterine FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology May 5, 2010 About
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of microwave endometrial ablation Introduction This overview has been prepared to assist
More informationExcessive menstrual blood loss
Ian Chilcott Excessive menstrual blood loss >80mls - That interferes with physical, emotional, social and material quality of life 1 in 20 women aged 30 to 49 years consult their GP each year with menorrhagia
More informationAbnormal uterine bleeding:
Primary Care Women s Health Forum 16th June 2010 Abnormal uterine bleeding: The University Of Birmingham T Justin Clark MD (Hons), MRCOG Consultant Obstetrician and Gynaecologist Birmingham Women s Hospital
More informationComparison of Office Hysteroscopy, Transvaginal Ultrasonography and Endometrial Biopsy in Evaluation of Abnormal Uterine Bleeding
JSLS Comparison of Office Hysteroscopy, Transvaginal Ultrasonography and Endometrial Biopsy in Evaluation of Uterine Bleeding Lubna Pal, MD, L. Lapensee, MD, T.L. Toth, MD, K.B. Isaacson, MD ABSTRACT INTRODUCTION
More informationPrevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*
FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term
More informationMedical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health
Medical Management of Fibroids Esmya Dr Paula Briggs Consultant in Sexual and Reproductive Health Treatment options for Uterine Fibroids ESMYA Selective Uterine Artery Embolisation Fibroid ablation (hysteroscopic
More informationAUB. Postmenopausal. Approximately 1 of every 8 postmenopausal. Rule out endometrial cancer first OBG COVER ARTICLE
OBG MANAGEMENT COVER ARTICLE Postmenopausal AUB Rule out endometrial cancer first When a postmenopausal woman presents with abnormal uterine bleeding, endometrial cancer is the biggest concern. But a host
More informationEndometrial line thickness in different conditions.
Endometrial line thickness in different conditions 1 Endometrial thickens in response to Rising estrogen levels during the menstrual cycle and then shedding endometrial at the times of menses 2 The thickens
More informationRole of diagnostic hysteroscopy in evaluation of abnormal uterine bleeding and its histopathological correlation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chaudhari KR et al. Int J Reprod Contracept Obstet Gynecol. 2014 Sep;3(3):666-670 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationClassification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women
60 CANCER CYTOPATHOLOGY Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women Edi Brogi, M.D., Ph.D. Rosemary Tambouret, M.D. Debra A. Bell, M.D. Department
More informationManagement of Endometrial Hyperplasia
Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New
More informationA randomised trial comparing the H Pipelle with the standard Pipelle for endometrial sampling at no-touch (vaginoscopic) hysteroscopy
DOI: 10.1111/j.1471-0528.2008.01992.x www.blackwellpublishing.com/bjog Gynaecological surgery A randomised trial comparing the H Pipelle with the standard Pipelle for endometrial sampling at no-touch (vaginoscopic)
More informationDisclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent
17β Estradiol/Progesterone in a Single Oral Softgel Capsule (TX 001HR) Significantly Reduced Moderate to Severe Vasomotor Symptoms without Endometrial Hyperplasia Disclosures Research support: Actavis,
More informationHysteroscopy - current trends and challenges
J Obstet Gynecol India Vol. 58, No. 1 : January/February 2008 pg 57-62 Original Article Hysteroscopy - current trends and challenges Gour A, Zawiejska A, Mettler L Department of Obstetrics and Gynaecology,
More informationColumbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3
17β-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia Rogerio A Lobo, MD 1 ; David F Archer,
More informationSummary CHAPTER 1. Introduction
Summary This thesis aims to evaluate the diagnostic work-up in postmenopausal women presenting with abnormal vaginal bleeding. The Society of Dutch Obstetrics and Gynaecology composed a guideline, which
More informationA randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome at four years
British Journal of Obstetrics and Gynaecology April 1999, Vol106, pp. 360-366 A randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome
More informationManagement of Endometrial Hyperplasia
Management of Endometrial Hyperplasia Green-top Guideline No. 67 RCOG/SGE Joint Guideline February 2016 Management of Endometrial Hyperplasia This is the first edition of this guideline.this is a joint
More informationMedical treatment for uterine fibroids
Medical treatment for uterine fibroids Prof Mary Ann Lumsden Prof of Gynaecology and Medical Education University of Glasgow Senior Vice President RCOG Conflict of Interest Chair, Guideline development
More informationFibroid mapping. Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital
Fibroid mapping Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital Fibroids Common condition >70% of women by onset of menopause.
More informationEndometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy
l FERTLTY AND STERLTY Vol. 62, 6, December 1994 Copyright e 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Endometrial ablation for refractory postmenopausal bleeding with continuous
More informationGynecologic Decision Making Based on Sonographic Findings
Gynecologic Decision Making Based on Sonographic Findings Mindy Goldman, MD Department of Obstetrics & Gynecology & Vickie A. Feldstein, MD Department of Radiology University of California, San Francisco
More informationSaid Saleh. Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
ARC Journal of Gynecology and Obstetrics Volume 1, Issue 2, 2016, PP 7-12 ISSN No. (Online) 2456-0561 http://dx.doi.org/10.20431/2456-0561.0102003 www.arcjournals.org Efficacy and Acceptability of two
More informationMenorrhagia Update. Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland
Menorrhagia Update Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland What is it? Subjective Excessive blood loss at time of menstruation flooding heavy clots Objective > 80mls volume
More informationDr Mary Birdsall. Fertility Associates Auckland
Dr Mary Birdsall Fertility Associates Auckland Period Problems Mary Birdsall Medical Director Fertility Associates Auckland Period Problems Basic Physiology No Periods Irregular Periods Heavy Periods
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationInternational Journal of Medical and Health Sciences
International Journal of Medical and Health Sciences Journal Home Page: http://www.ijmhrs.net ISSN:2277-4505 Original article Comparison Of Imaging Modalities In Abnormal Uterine Bleeding : Correlation
More informationCorrelation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding
DOI 10.1007/s13224-014-0627-z ORIGINAL ARTICLE Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding Singh Pushpa Dwivedi Pooja Mendiratta Shweta
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of laparoscopic laser myomectomy Introduction This overview has been prepared to assist
More informationCervical Cancer - Suspected
Cervical Cancer - Suspected Presentation for patients Asymptomatic presentation Symptomatic presentation History and examination Consider differential diagnoses RED FLAG! Cervix appears normal after examination
More informationHysteroscopic polypectomy in 240 premenopausal and postmenopausal women
Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women Sangchai Preutthipan, M.D., and Yongyoth Herabutya, F.R.C.O.G. Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi
More informationCitation for published version (APA): Timmermans, A. (2009). Postmenopausal bleeding : studies on the diagnostic work-up
UvA-DARE (Digital Academic Repository) Postmenopausal bleeding : studies on the diagnostic work-up Timmermans, A. Link to publication Citation for published version (APA): Timmermans, A. (2009). Postmenopausal
More informationChapter 2. Implementation of hysteroscopic surgery in The Netherlands. Heleen van Dongen Wendela Kolkman Frank Willem Jansen
Chapter 2 Implementation of hysteroscopic surgery in The Netherlands Heleen van Dongen Wendela Kolkman Frank Willem Jansen Adapted from Eur J Obstet Gynecol Reprod Biol 07;132:232-236 Introduction Diagnostic
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of balloon thermal endometrial ablation (Cavaterm) Introduction This overview has been prepared
More informationCorrespondence should be addressed to Ammar Cherkess Al-Rikabi; ammar
International Reproductive Medicine, Article ID 578193, 5 pages http://dx.doi.org/10.1155/2014/578193 Research Article Adequacy of the Endometrial Samples Obtained by the Uterine Explora Device and Conventional
More informationHysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding
FERTILITY AND STERILITY Copyright 1996 American Society for Reproductive Medicine Vol. 65, No, 6, June 1996 Printed on acid-free paper in U. S. A Hysteroscopy in women with abnormal uterine bleeding on
More informationModern Management of Fibroids
Modern Management of Fibroids Mr Narendra Pisal The Portland Hospital Fibroids Very common 20-40% of all women Up to 80% of black women by 50y Most fibroids are asymptomatic 50% will have significant symptoms
More informationSubject Index. Cavaterm, endometrial ablation complications 146, 150 contraindications 152 cost analysis compared with hysterectomy
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Abnormal uterine bleeding, see also Adenomyosis, Endometrial cancer, Menorrhagia dilatation and curettage 21, 22, 25 hysteroscopy of premenopausal women anesthesia
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 22499571 Original Research Article Role of Hysteroscopy Vs Transvaginal Sonography in Diagnosis of Abnormal Uterine Dr. Preeti
More informationPredicting Intracavitary Lesions Based on Stringent Histologic Criteria to Diagnose Endometrial Polyps
Predicting Intracavitary Lesions Based on Stringent Histologic Criteria to Diagnose Endometrial Polyps Amin A. Ramzan, MD 1 ; Paulette Mhawech-Fauceglia, MD 2 ; Brian Kay, MD 2 ; Teodulo Meneses, MD 2
More informationNon-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml
More informationEndometriosis. *Chocolate cyst in the ovary
Endometriosis What is endometriosis? Endometriosis is a common condition in young women. It's chronic, painful, and it often progressively gets worse over the time. *Chocolate cyst in the ovary Normally,
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationNICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88
Heavy menstrual bleeding: assessment and management NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationSURGICAL PROBLEMS IN FERTILITY- FIBROIDS. Dr.Māris Arājs gyn-ob specialist Cell phone:
SURGICAL PROBLEMS IN FERTILITY- FIBROIDS Dr.Māris Arājs gyn-ob specialist maris@myclinicriga.lv Cell phone: +371 26556466 There is NO Industry Sponsorship and Financial Conflict of Interest for this presentation
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationPrimary Care Gynaecology Guidelines: HEAVY REGULAR MENSTRUAL BLEEDING
Primary Care Guidelines: HEAVY REGULAR MENSTRUAL BLEEDING
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More informationInvestigating HMB- an evidence based approach
BSGE Meeting: Contemporary management of heavy menstrual bleeding (HMB) in primary and secondary care: (7 th December 2018, RCOG) Investigating HMB- an evidence based approach T. Justin Clark MB ChB, MD(Hons),
More informationTransvaginal ultrasonography and hysteroscopy in postmenopausal bleeding a prospective study
Acta Obstet Gynecol Scand 2001; 80: 856 862 Copyright C Acta Obstet Gynecol Scand 2001 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationHysterectomy : A Clinicopathologic Correlation
Bahrain Medical Bulletin, Vol. 28, No.2, June 2006 Hysterectomy : A Clinicopathologic Correlation Layla S Abdullah, FRCPC* Objective : To study the most common pathologies identified in hysterectomy specimens
More informationOne of the commonest gynecological cancers,especially in white Americans.
Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in
More informationAbnormal Uterine Bleeding. Richard Dover Specialist gynaecologist
Abnormal Uterine Bleeding Richard Dover Specialist gynaecologist A pragmatic guide. Wide topic range What s not coming up Precocious puberty Menorrhagia well maybe just a little Topics Adolescents IMB
More informationDr. Mojibian. Menopause
Dr. Mojibian Menopause I. Introduction - The term menopause is derived from Greek Meno (months) and pause (cessation). The word means cessation of menstruation. - Cliamacteric which is by dictionary definition
More informationCynthia Morris DO, FACOOG, FACOS Medical Director, Women s Wellness Center Fayette County Memorial Hospital
Cynthia Morris DO, FACOOG, FACOS Medical Director, Women s Wellness Center Fayette County Memorial Hospital Touchdown to CME Eighth District Academy of Osteopathic Medicine & Surgery October 8. 2017 Goals
More informationFraser IS, 1 Parke S, 2 Mellinger U, 2 Machlitt A, 2 Jensen JT 4
An oral contraceptive comprising oestradiol valerate/dienogest is effective in the treatment of heavy and/or prolonged menstrual bleeding: a pooled analysis Fraser IS, 1 Parke S, 2 Mellinger U, 2 Machlitt
More informationOffice hysteroscopy after ultrasonographic diagnosis of thickened endometrium in postmenopausal patients
Gynecol Surg (2009) 6:317 322 DOI 10.1007/s10397-009-0485-3 ORIGINAL ARTICLE Office hysteroscopy after ultrasonographic diagnosis of thickened endometrium in postmenopausal patients Alexandra Cordeiro
More informationIndian Journal of Basic and Applied Medical Research; September 2015: Vol.-4, Issue- 4, P
Original article: To study post intrauterine insemination conception rate among infertile women with polyp and women with normal uterine endometrium cavity 1Dr. Archana Meena, 2 Dr. Renu Meena, 3 Dr. Kusum
More informationMEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationChawla Indu Tripathi Suchita Vohra Poonam Singh Pushpa
DOI 10.1007/s13224-013-0501-4 ORIGINAL ARTICLE To Evaluate the Accuracy of Saline Infusion Sonohysterography (SIS) for Evaluation of Uterine Cavity Abnormalities in Patients with Abnormal Uterine Bleeding
More informationGynaecological Oncology Cases
Gynaecological Oncology Cases 1. Tamoxifen and the endometrium 2. Cancer and the older woman Dr Julie M Lamont Consultant Gynaecological Oncologist Epworth Freemasons Hospital 21 st April 2015 Mrs FS 66
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health and social care directorate. Quality standards and indicators.
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health and social care directorate Quality standards and indicators Briefing paper Quality standard topic: Heavy menstrual bleeding Output: Prioritised
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationCancer Risks of Ovulation Induction
Cancer Risks of Ovulation Induction 5th World Congress on Ovulation Induction September 13-15, 2007 Louise A. Brinton, Ph.D. National Cancer Institute Rockville, Maryland, USA Ovulation Induction and Cancer
More informationPALM-COEIN: Your AUB Counseling Guide
PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural
More informationThe Study of Tamoxifen and Raloxifene (STAR): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s The Study of Tamoxifen
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationConflicts 10/5/2016. Abnormal Uterine Bleeding. Objectives Review diagnosis and updated nomenclature. Management options for acute and chronic AUB.
Abnormal Uterine Bleeding Barbara L. Keller, MD JD Naval Hospital Oak Harbor OB/GYN Physician Conflicts I have no conflicts or financial interests to disclose. Objectives Review diagnosis and updated nomenclature.
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationCLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION
Donald L. Renfrew, MD Radiology Associates of the Fox Valley, 333 N. Commercial Street, Suite 100, Neenah, WI 54956 2/12/2011 Radiology Quiz of the Week # 7 Page 1 CLINICAL PRESENTATION AND RADIOLOGY QUIZ
More informationArdhanu Kusumanto Oktober Contraception methods for gyne cancer survivors
Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management
More informationMenopause & HRT. Matt McKenna Elliot Davis
Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationDr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre
Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre AUB Outline Terminology Classification/Etiology Assessment Treatment Referral to Gynaecology U c pt 4
More informationThe reproductive lifespan
The reproductive lifespan Reproductive potential Ovarian cycles Pregnancy Lactation Male Female Puberty Menopause Age Menstruation is an external indicator of ovarian events controlled by the hypothalamicpituitary
More informationDIAGNOSTIC HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING & IT'S HISTOPATHOLOGIC CORRELATION: OUR EXPERIENCE
Original Article DIAGNOSTIC HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING & IT'S HISTOPATHOLOGIC CORRELATION: OUR EXPERIENCE Abstract : 1 2 3 4 Neetha Nandan, Lakshmi Manjeera, Supriya Rai & Mangala Gowri
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationGLOBAL ENDOMETRIAL ABLATION TECHNOLOGY
GLOBAL ENDOMETRIAL ABLATION TECHNOLOGY Training: Part 1 Anatomy and Physiology Female Anatomy Normal Uterus Female Anatomy Normal Uterus Female Anatomy Uterine Positions Abnormal Uterus Retroflexed Normal
More informationCurrent approaches to managing heavy menstrual bleeding
Drug review Heavy menstrual bleeding Current approaches to managing heavy menstrual bleeding Jasmine Tay BM BS, Shruti Mohan MRCOG and Jenny Higham FRCOG SPL The choice of drug treatment for heavy menstrual
More informationVirtaMed GynoS hysteroscopy Module descriptions
VirtaMed GynoS hysteroscopy Module descriptions VirtaMed AG Rütistr. 12, 8952 Zurich Switzerland info@virtamed.com www.virtamed.com Phone: +41 44 500 9690 Table of contents Table of contents... 1 Essential
More informationPostmenopausal Asymptomatic. Endometrial Thickening: Patient. Characteristics and Pathology
Research Article imedpub Journals www.imedpub.com Womens Health and Reproductive Medicine Abstract Postmenopausal Asymptomatic Endometrial Thickening: Patient Characteristics and Pathology Background:
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationChapter 4. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomised controlled study among residents in training
Chapter 4 Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomised controlled study among residents in training Heleen van Dongen Mark Hans Emanuel Ron Wolterbeek J. Baptist
More informationOver the past year, a few gems have been
UPDATE Abnormal uterine bleeding Howard T. Sharp, MD Dr. Sharp is Professor and Vice Chair for Clinical and Quality Activities, Department of Obstetrics and Gynecology, University of Utah Health Sciences
More informationTreatment of Heavy Menstrual Bleeding: Ludkin (Nurse Hysteroscopist, Bradford Royal Infirmary) & M Rogers (Advanced
Treatment of Heavy Menstrual Bleeding: Nov 14 th 2013- Authors: Prof Sian Jones (Gynaecologist, Bradford Royal Infirmary, H Ludkin (Nurse Hysteroscopist, Bradford Royal Infirmary) & M Rogers (Advanced
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More information